Turner JH - Search Results

1

Turner JH. Turner JH. Cancer Biother Radiopharm. 2023 Feb;38(1):1-7. doi: 10.1089/cbr.2022.0082. Epub 2022 Dec 9. Cancer Biother Radiopharm. 2023. PMID: 36493375 Review.

2

Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131.

De Decker M, Turner JH. De Decker M, et al. Among authors: turner jh. Cancer Biother Radiopharm. 2012 Feb;27(1):72-6. doi: 10.1089/cbr.2011.1073. Epub 2011 Dec 7. Cancer Biother Radiopharm. 2012. PMID: 22149590

3

Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.

Kruger PC, Cooney JP, Turner JH. Kruger PC, et al. Among authors: turner jh. Cancer Biother Radiopharm. 2012 Nov;27(9):552-60. doi: 10.1089/cbr.2012.1275. Epub 2012 Oct 12. Cancer Biother Radiopharm. 2012. PMID: 23062193 Clinical Trial.

4

Perspective: multimodality radionuclide therapy of progressive disseminated lymphoma and neuroendocrine tumors as a paradigm for cancer control.

Turner JH. Turner JH. Cancer Biother Radiopharm. 2012 Nov;27(9):525-9. doi: 10.1089/cbr.2012.1274. Epub 2012 Oct 12. Cancer Biother Radiopharm. 2012. PMID: 23062194 No abstract available.

5

Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.

Boucek JA, Turner JH. Boucek JA, et al. Among authors: turner jh. Cancer Biother Radiopharm. 2014 Feb;29(1):18-25. doi: 10.1089/cbr.2013.1490. Epub 2013 Oct 17. Cancer Biother Radiopharm. 2014. PMID: 24134141

6

NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study.

Claringbold PG, Turner JH. Claringbold PG, et al. Among authors: turner jh. Cancer Biother Radiopharm. 2015 Aug;30(6):261-9. doi: 10.1089/cbr.2015.1876. Cancer Biother Radiopharm. 2015. PMID: 26181854 Clinical Trial.

7

Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice.

Kesavan M, Turner JH, Meyrick D, Yeo S, Cardaci G, Lenzo NP. Kesavan M, et al. Among authors: turner jh. Cancer Biother Radiopharm. 2018 Sep;33(7):274-281. doi: 10.1089/cbr.2017.2403. Epub 2018 Jul 10. Cancer Biother Radiopharm. 2018. PMID: 29989440

8

Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What's More.

Turner JH. Turner JH. Cancer Biother Radiopharm. 2019 Apr;34(3):135-140. doi: 10.1089/cbr.2019.29006.jht. Cancer Biother Radiopharm. 2019. PMID: 30973278 No abstract available.

9

Ethics of Pharma Clinical Trials in the Era of Precision Oncology.

Turner JH. Turner JH. Cancer Biother Radiopharm. 2021 Feb;36(1):1-9. doi: 10.1089/cbr.2020.4129. Epub 2020 Sep 15. Cancer Biother Radiopharm. 2021. PMID: 32935997

10

Prospect of Cure in Cancer Care.

Turner JH. Turner JH. Cancer Biother Radiopharm. 2021 Apr;36(3):231-236. doi: 10.1089/cbr.2020.4621. Epub 2021 Jan 7. Cancer Biother Radiopharm. 2021. PMID: 33416438 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

244 results

Search Page